Analyst Price Target Update on AMAG Pharmaceuticals (NASDAQ:AMAG)

AMAG Pharmaceuticals (NASDAQ:AMAG): 7 Analyst have given the stock of AMAG Pharmaceuticals (NASDAQ:AMAG) a near short term price target of $46.29. The standard deviation reading, which is a measure by which the stock price is expected to swing away from the mean estimate, is at $18.15. The higher price target estimate is at $80 while the lower price estimates are fixed at $27.

Many analysts have stated their opinion on the company shares. Equity Analysts at the Raymond James downgrades the rating on AMAG Pharmaceuticals (NASDAQ:AMAG). The brokerage firm has issued a Market Perform rating on the shares. The shares were previously rated Outperform. The rating by the firm was issued on May 4, 2016. For the current week, the company shares have a recommendation consensus of Buy.

On the companys insider trading activities, Fallon John A., director of Amag Pharmaceuticals Inc., executed a transaction worth $100,776 on November 10, 2015. A total of 3,230 shares were purchased at an average price of $31.2. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.

AMAG Pharmaceuticals (NASDAQ:AMAG) : On Monday heightened volatility was witnessed in AMAG Pharmaceuticals (NASDAQ:AMAG) which led to swings in the share price. The stock opened for trading at $20.92 and hit $22.21 on the upside , eventually ending the session at $21.795, with a gain of 3.59% or 0.755 points. The heightened volatility saw the trading volume jump to 1,005,310 shares. The 52-week high of the share price is $77.73 and the company has a market cap of $754 million. The 52-week low of the share price is at $17.92 .

AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on maternal health, anemia and cancer supportive care. The Company markets Makena (hydroxyprogesterone caproate injection), Feraheme (ferumoxytol) Injection for Intravenous (IV) use and MuGard Mucoadhesive Oral Wound Rinse. Feraheme is an IV iron replacement therapy for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD). Feraheme is approved for marketing in the United States. Makena is a drug indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. MuGard is indicated for the management of oral mucositis/stomatitis and all types of oral wounds, including aphthous ulcers/canker sores and traumatic ulcers, such as those caused by oral surgery or ill-fitting dentures or braces.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *